As such, drugs acting at 5-HT2A receptors, like (R)-DOI, may represent a novel class of superpotent small molecule inhibitors of TNF-α pathway signaling with therapeutic potential for treating not only atherosclerosis but also other inflammatory conditions involving TNF-α , that are more then 100-fold more potent than the more potent steroidal anti-inflammatories currently on the market. This evidence concerns the gene TNF and atherosclerosis.